anti-PD(L)1 therapy
1 abstract
Abstract
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.Org: Flatiron Health, San Francisco, CA, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Flatiron Health, New York, NY, Flatiron Health, Dallas, TX,